Cereno Scientific, Capital Markets Day, 2023

Cereno Scientific, ett bolag som utvecklar innovativa behandlingar för vanliga och sällsynta kardiovaskulära sjukdomar, meddelade idag ytterligare information om bolagets kommande kapitalmarknadsdag som kommer att hållas den 30 augusti 2023. Vi bjuder in analytiker, investerare samt finansiell media att delta för att få insikt i vår strategi och verksamhet.

Programmet ska ge en uppdatering om Cerenos projektportfölj, klinisk och preklinisk utveckling samt tillväxtstrategin från både bolaget samt externa samarbetspartners. En detaljerad agenda kommer att delas före eventet.

Agenda: 

08.30 Welcome

08.35 Cereno’s Commitment to Transforming Cardiovascular Disease Management . Sten R. Sörensen - CEO Cereno. 

• Company overview.
•  Strategy, growth and market potential.

08.45 Understanding PAH: Debilitating Rare Disease. Dr. Raymond Benza - System Director of Pulmonary Hypertension at Mount Sinai Icahn School of Medicine, New York City.

• Medical need.
• Current treatment options.
• Need for better disease-modifying therapies.

08.55 CardioMEMS – Phase II Clinical Collaboration Between Abbott and Cereno. Dr. Phil B. Adamson - Divisional Vice President and Chief Medical Officer Heart Failure Division, Abbott. 

• Mutually beneficial collaboration between Abbot and Cereno.
• CardioMEMS HF System unique functionality.
• Advantage of using CardioMEMS in a clinical trial.

09.05 Cereno’s CS1 in Phase II study design. Dr. Raymond Benza. 

• Innovative and effective Phase II study design – why it’s advantageous.
• Smart and efficient measurements of study endpoints.

09.15 Cereno’s CS1 Phase II study status. Dr. Björn Dahlöf - Chief Medical Officer, Cereno.

• Update of current status in the study.
• Progress with clinics. 
• Mitigation strategies deployed.

09.25 CS1: Remarkable patient case study data. Dr. Raymond Benza.

• Findings indicating CS1’s efficacy in PAH. 
• Comparison with other treatment alternatives.

09.35 CS1: Launching data quality control initiative in Phase II study. Dr. Björn Dahlöf - Chief Medical Officer, Cereno.

•  Rationale and method.
• Expected outcome and timeline.

09.45 Medical need in CVD – new strategies to meet growing prevalence. Dr. Björn Dahlöf - Chief Medical Officer, Cereno.

• Cereno’s preclinical programs.
• High need of prevention strategies.

09.50 Preclinical programs with potential in thrombosis without increased risk of bleeding. Dr. Michael Holinstat - Prof. at University of Michigan Medical School; and Director Translation Research, Cereno.

• Present preclinical data for CS014 and its properties. 
• Present preclinical data for CS585 and its properties.

10.05 Q&A

10.20 Concluding Words. Sten R. Sörensen - CEO Cereno.

• Briefly about the CVD market opportunity for Cereno. 
• The road ahead (pipeline timeline).